Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial
NAC combined with dual immune checkpoint inhibitors is feasible for advanced-stage EOC and shows promising activity with a durable clinical response.
Authors
- Junsik Park (ORCID: https://orcid.org/0000-0003-4094-2097)
- Myong Cheol Lim (ORCID: https://orcid.org/0000-0001-8964-7158)
- Hee Seung Kim (ORCID: https://orcid.org/0000-0003-1238-7604)
- Jae‐Weon Kim (ORCID: https://orcid.org/0000-0003-1835-9436)
- Byoung‐Gie Kim (ORCID: https://orcid.org/0000-0002-0572-8450)
- Je‐Gun Joung (ORCID: https://orcid.org/0000-0003-2859-1036)
- Chel Hun Choi (ORCID: https://orcid.org/0000-0002-0199-6669)
- Jung-Bok Lee (ORCID: https://orcid.org/0000-0002-1420-9484)
- Jung‐Yun Lee (ORCID: https://orcid.org/0000-0001-7948-1350)
- Eunhyang Park (ORCID: https://orcid.org/0000-0003-2658-5054)
- Sunghoon Kim (ORCID: https://orcid.org/0000-0002-1645-7473)
- Sang‐Yoon Park (ORCID: https://orcid.org/0000-0001-8325-6009)
- So‐Jin Shin (ORCID: https://orcid.org/0000-0002-7432-6025)
Institutions
- Ulsan College (KR)
- Seoul National University (KR)
- Yonsei University (KR)
- Soonchunhyang University (KR)
- Soonchunhyang University Hospital Seoul (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- New Generation University College (ET)
- University of Ulsan (KR)
- National Cancer Center (US)
- National Cancer Center (KR)
- Keimyung University Dongsan Medical Center (KR)
- CHA University (KR)
- Keimyung University (KR)
- Bucheon University (KR)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3753
- Citations
- 2
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.40